---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-071014"
form_type: "8-K/A"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:34:40.628098+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sagimet reports positive Phase 2b MASH data for denifanstat; primary endpoints met

## Summary
- Primary endpoints achieved: ≥2-point NAS reduction without fibrosis worsening (38% vs 16%, p=0.0035) and MASH resolution (26% vs 11%, p=0.0173) in ITT.
- Fibrosis improvement ≥1 stage without MASH worsening: ITT 30% vs 14% (p=0.0199); F3 subgroup 49% vs 13% (p=0.0032).
- Fibrosis improvement ≥2 stages: mITT 20% vs 2% (p=0.0065); F3 34% vs 4% (p=0.0050).
- No treatment-related SAEs; discontinuation rate 19.6% denifanstat vs 5.4% placebo.
- Company plans to initiate Phase 3 registrational program for denifanstat in MASH in H2 2024.

## SEC filing metadata
- accession: 0001104659-24-071014
- form_type: 8-K/A
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465924071014/0001104659-24-071014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465924071014/tm2417159d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-071014
- JSON: https://secwatch.observer/filing/0001104659-24-071014.json
- Plain text: https://secwatch.observer/filing/0001104659-24-071014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.